Growth hormone receptor inhibition decreases the growth and metastasis of pancreatic ductal adenocarcinoma

Ramadevi Subramani, Rebecca Lopez-Valdez, Alyssa Salcido, Thiyagarajan Boopalan, Arunkumar Arumugam, Sushmita Nandy, Rajkumar Lakshmanaswamy

Experimental & Molecular Medicine · 2014 · 41 citations · 29 references

DOIFull text

Open access

Concepts

Abstract

Pancreatic cancer is the only major cancer with very low survival rates (1%). It is the fourth leading cause of cancer-related death. Hyperactivated growth hormone receptor (GHR) levels have been shown to increase the risk of cancer in general and this pathway is a master regulator of key cellular functions like proliferation, apoptosis, differentiation, metastasis, etc. However, to date there is no available data on how GHR promotes pancreatic cancer pathogenesis. Here, we used an RNA interference approach targeted to GHR to determine whether targeting GHR is an effective method for controlling pancreatic cancer growth and metastasis. For this, we used an in vitro model system consisting of HPAC and PANC-1 pancreatic cancer cells lines. GHR is upregulated in both of these cell lines and silencing GHR significantly reduced cell proliferation and viability. Inhibition of GHR also reduced the metastatic potential of pancreatic cancer cells, which was aided through decreased colony-forming ability and reduced invasiveness. Flow cytometric and western blot analyses revealed the induction of apoptosis in GHR silenced cells. GHR silencing affected phosphatidylinositol 3 kinase/AKT, mitogen extracellular signal-regulated kinase/extracellular signal-regulated kinase, Janus kinase/signal transducers and activators of transcription and mammalian target of rapamycin signaling, as well as, epithelial to mesenchymal transition. Interestingly, silencing GHR also suppressed the expression of insulin receptor-β and cyclo-oxygenease-2. Altogether, GHR silencing controls the growth and metastasis of pancreatic cancer and reveals its importance in pancreatic cancer pathogenesis. A viable treatment for pancreatic cancer could stem from targeting the growth hormone receptor (GHR) protein, scientists in the USA state. Pancreatic cancer shows no early warning symptoms, and, as a result, is one of the most lethal forms of cancer, with a survival rate of only 1%. Following limited earlier studies showing elevated levels of GHR in patients with the disease, Rajkumar Lakshmanaswamy and co-workers at Texas Tech University Health Sciences Center studied the impact of GHR levels on the development of pancreatic cancer. The team conducted tests on human cancer cell lines, and discovered that silencing GHR significantly reduced the proliferation and invading ability of the pancreatic cancer cells. Lakshmanaswamy's team believe that GHR may be a viable therapeutic target for pancreatic cancer.

References

29